Request Demo
Last update 29 Mar 2025
NB-002(NeoLogics Bioscience)
Last update 29 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms NB 002, NB-002, NB002 |
Target |
Action inhibitors |
Mechanism TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with NB-002(NeoLogics Bioscience)NCT05924906
Phase 1a/1b, First-in-Human, Open Label, Dose Escalation and Dose Expansion Study of NB002, a Multifunctional TIM-3 Blocking Antibody, in Subjects With Advanced or Metastatic Solid Tumors
100 Clinical Results associated with NB-002(NeoLogics Bioscience)
Login to view more data
100 Translational Medicine associated with NB-002(NeoLogics Bioscience)
Login to view more data
100 Patents (Medical) associated with NB-002(NeoLogics Bioscience)
Login to view more data
100 Deals associated with NB-002(NeoLogics Bioscience)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic Solid Tumor | Phase 1 | - | 01 Oct 2023 | |
| Neoplasms | Phase 1 | China | 04 Apr 2023 | |
| Hematologic Neoplasms | Preclinical | China | 19 Apr 2023 | |
| Solid tumor | Preclinical | China | 19 Apr 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free